Some TGFβ inhibitors are already at the late stages of disease-specific clinical trials: phase I/II in combination with radiotherapy and fresolimumab (TGFβ inhibitor) in non-small cell lung cancer and metastatic breast cancer. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.